Abstract
Recent progress in enzyme engineering has led to versions of human butyrylcholinesterase (BChE) that hydrolyze cocaine efficiently in plasma, reduce concentrations reaching reward neurocircuity in the brain, and weaken behavioral responses to this drug. Along with enzyme advances, increasingly avid anti-cocaine antibodies and potent anti-cocaine vaccines have also been developed. Here we review these developments and consider the potential advantages along with the risks of delivering drug-intercepting proteins via gene transfer approaches to treat cocaine addiction.
Keywords: Adeno-associated viral vector, butyrylcholinesterase, cocain hydrolase, cocaine vaccine, gene therapy, helper-dependent viral vector, monoclonal antibody, keyhole limpet hemocyanin, hydrolytic cleavage, BChE, Cocaine, Cytomegalovirus
CNS & Neurological Disorders - Drug Targets
Title: Interception of Cocaine by Enzyme or Antibody Delivered with Viral Gene Transfer: A Novel Strategy for Preventing Relapse in Recovering Drug Users
Volume: 10 Issue: 8
Author(s): Stephen Brimijoin
Affiliation:
Keywords: Adeno-associated viral vector, butyrylcholinesterase, cocain hydrolase, cocaine vaccine, gene therapy, helper-dependent viral vector, monoclonal antibody, keyhole limpet hemocyanin, hydrolytic cleavage, BChE, Cocaine, Cytomegalovirus
Abstract: Recent progress in enzyme engineering has led to versions of human butyrylcholinesterase (BChE) that hydrolyze cocaine efficiently in plasma, reduce concentrations reaching reward neurocircuity in the brain, and weaken behavioral responses to this drug. Along with enzyme advances, increasingly avid anti-cocaine antibodies and potent anti-cocaine vaccines have also been developed. Here we review these developments and consider the potential advantages along with the risks of delivering drug-intercepting proteins via gene transfer approaches to treat cocaine addiction.
Export Options
About this article
Cite this article as:
Brimijoin Stephen, Interception of Cocaine by Enzyme or Antibody Delivered with Viral Gene Transfer: A Novel Strategy for Preventing Relapse in Recovering Drug Users, CNS & Neurological Disorders - Drug Targets 2011; 10(8) . https://dx.doi.org/10.2174/187152711799219398
DOI https://dx.doi.org/10.2174/187152711799219398 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Leucine-zipper and Sterile-α Motif Kinase (ZAK): A Potential Target for Drug Discovery
Current Medicinal Chemistry Hyperglycemia-induced Oxidative Stress and its Role in Diabetes Mellitus Related Cardiovascular Diseases
Current Pharmaceutical Design Comparison of Clinical Outcomes Between Genders Following Antihypertensive Therapy: A Meta-Analysis
Current Medicinal Chemistry Obstetric Anaesthesia and Obesity
Current Women`s Health Reviews The Protein-Protein Interaction-Mediated Inactivation of PTEN
Current Molecular Medicine Dietary Fish Oil Reduces Colon Cancer Risk
Current Organic Chemistry The Importance of NAD in Multiple Sclerosis
Current Pharmaceutical Design Therapeutic Exploitation of Endogenous Anti-Inflammatory Mechanisms:Old and New Leads
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Pathobiology of Endothelin-1 in Vein Graft Disease: Are ETA Receptor Antagonists the Solution to Prevent Vein Graft Failure?
Current Vascular Pharmacology Stress Echocardiography
Current Pharmaceutical Design Stem Cell Therapy in Heart Diseases: A Review of Selected New Perspectives,Practical Considerations and Clinical Applications
Current Cardiology Reviews Endothelin Receptor Antagonists: Another Potential Alternative for Cardiovascular Diseases
Current Drug Targets - Cardiovascular & Hematological Disorders Construction, Expression, Purification and Immunology Effect of an Antiatherosclerosis Chimeric Enzyme Vaccine in Escherichia coli
Protein & Peptide Letters New Biochemical Markers in Acute Coronary Syndromes
Current Medicinal Chemistry Effects of Dietary Intake and Supplementation of Fatty Acids on Cardiometabolic Disorders in Humans: a Lesson from a Large Number of Meta-Analyses
Letters in Drug Design & Discovery Myocardial Insulin Resistance and Cardiac Complications of Diabetes
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Editorial (Thematic Issue: The Long Way to a Successful Medical Therapy of Heart Failure with Beta-blockers in Children with Heart Disease)
Reviews on Recent Clinical Trials The Effects of Antihypertensive Therapy on Haemostatic Parameters
Current Pharmaceutical Design Neuroprotection by Natural Polyphenols: Molecular Mechanisms
Central Nervous System Agents in Medicinal Chemistry Von Willebrand Factor: Drug and Drug Target
Cardiovascular & Hematological Disorders-Drug Targets